U.S., Feb. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07417241) titled 'SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study' on Feb. 11.
Brief Summary: This is a prospective, multicenter, open-label, randomized, controlled Study. The purpose of this study is to evaluate the efficacy and safety of SHR-A1811 versus pyrotinib plus capecitabine in the treatment of trastuzumab primary-resistant HER2-positive advanced breast cancer.
Study Start Date: March 31
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
HER2-positive Breast Cancer
Intervention:
DRUG: SHR-A1811
4.8 mg/kg administered as an intravenous infusion on Day 1 of each cycle. 3 wee...